Using existing drugs to treat cervical cancer before standard treatment could lead to a 35% reduction in the risk of relapse or death, a new study suggests. Researchers from the UCL Cancer Institute and UCLH looked into whether a short course of induction chemotherapy (IC), where a drug is used to destroy as many cancer cells as possible, before chemoradiation (CRT), could help with this. Here’s everything you need to know about the findings… What is cervical cancer? According to the NHS website, cervical cancer is a type of cancer found anywhere near the cervix – the opening between the vagina and the womb (uterus), which is also known as the neck of the womb. Most cervical cancers grow very slowly and are caused by an infection from specific types of human papillomavirus (HPV) and mostly affect women under the age of 45. According to Jo’s Cervical Cancer Trust, symptoms include vaginal bleeding that is unusual to you, changes to vaginal discharge, discomfort during sex and pain in your lower back or pelvis. Changes to cells can be spotted by a cervical screening, and then treated before they turn into cancer. There are around 3,200 new cases every year in the UK, with the five-year survival rate being around 70%, according to Cancer Research UK. CRT has been the standard treatment for cervical cancer patients since 1999, but even though there have been overall significant developments in radiation therapy techniques, up to 30% of people experience their cancer coming back. What did the research involve? Over a 10-year period, 500 patients who had been diagnosed with cervical cancer – that was large enough to see without a microscope but hadn’t spread to other parts of the body – took part in the Interlace trial at hospitals in the UK, Mexico, India, Italy and Brazil. Researchers looked into whether a short course of IC before CRT could reduce rates of relapse and death. What results were found? After five years, researchers discovered that 80% of the people who received a combination of chemotherapy and radiotherapy were alive, whilst 73% had not seen their cancer return or spread. A major benefit, according to researchers, is that it can be incorporated into standard of care treatment relatively quickly, because cheap, accessible and already-approved ingredients such as carboplatin and paclitaxel are needed for IC. “Our trial shows that this short course of additional chemotherapy delivered immediately before the standard CRT can reduce the risk of the cancer returning or death by 35%,” said Dr Mary McCormack, lead investigator of the trial from UCL Cancer Institute and UCLH. “This is the biggest improvement in outcome in this disease in over 20 years. “I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere. “We couldn’t have done this without the generous support of Cancer Research UK.” Why is the research important? Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “Timing is everything when you’re treating cancer. The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results in this trial. “A growing body of evidence is showing the value of additional rounds of chemotherapy before other treatments like surgery and radiotherapy in several other cancers. “Not only can it reduce the chances of cancer coming back, it can be delivered quickly using drugs already available worldwide. “We’re excited for the improvements this trial could bring to cervical cancer treatment and hope short courses of induction chemotherapy will be rapidly adopted in the clinic.”

Many of Grado's headphones are prohibitively expensive, so we're happy to see that the top-end

An undeveloped piece of luxury Jumeirah Bay Island is snapped up by an unknown buyer for 125 million dirhams -- a little over $34 million -- showing that demand for high-end vacation home real estate in the emirate remains high despite global economic turmoil.

Great lessons can be learned from mistakes. Visit this museum to learn from others' failures.

AirPods, AirPods Pro, and AirPods Max can accumulate dirt and bacteria, which you don’t want

The rise of easily accessible generative AI means it's getting more difficult to know whether

The Bloomberg Invest conference resumed Thursday with some of the most influential leaders in finance gathering in New

By Michelle Nichols UNITED NATIONS (Reuters) -There are a "number of ideas being floated" to help get Ukrainian and Russian

SAVE $40: The Beats Studio Buds+ are on sale for $129.95 at Amazon as of

The Formula 1 paddock heads to Montreal next for the Canadian Grand Prix. Max Verstappen won his third race in a row with a cruise of a victory in Spain last time out, with his lead in the F1 world championship now 53 points from Red Bull team-mate Sergio Perez. COMMENT: Ferrari’s F1 flaws all the more baffling after shock success at Le Mans It was an improved weekend in Barcelona for Mercedes though, with their revamped car showing improvements as Lewis Hamilton and George Russell came home second and third respectively. There was disappointment for Fernando Alonso though, who only finished seventh, while Ferrari’s Charles Leclerc finished outside the points in 11th. Verstappen won last year’s race in Montreal, seeing off Carlos Sainz in second. FP1 on Friday was abandoned early on due to a CCTV issue at the track, while Lewis Hamilton was fastest in second practice later in the day. Follow live coverage from the Canadian Grand Prix with The Independent - FP3 starts at 5:30pm (BST). Read More Lewis Hamilton fastest as practice for Canadian Grand Prix finally gets started F1 Fantasy: How to play in 2023 season and top tips for Canadian Grand Prix Max Verstappen closes in on ‘amazing achievement’ of matching Ayrton Senna

Where and when to pop your Champagne is such a Wimbledon problem

A good book packs power